A Phase 2 interventional study of LY3009104 and Placebo in Arthritis, Rheumatoid, sponsored by Eli Lilly and Company. Completed at 68 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-06-16.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 11th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 2nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–65
Galvani Bioelectronics · Sites in United States, Netherlands
Ages 22–75
University of Nebraska · Sites in United States
Ages 19+
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 9
First in 2007; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 301 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 290 across the 23 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
35 studies in Arthritis, Rheumatoid by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 14th largest by enrollment, is one of 5 that started in 2010, is one of 13 in phase 2, and was the 7th registered.
Eli Lilly and Company’s Arthritis, Rheumatoid studies by the year they started, since 2005.
1 of the studies testing baricitinib in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 35 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate the safety and efficacy of LY3009104 in participants with Rheumatoid Arthritis (RA).
This study consists of the following:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
Drug: LY3009104 · Drug: Methotrexate
Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
Drug: LY3009104 · Drug: Methotrexate
Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
Drug: LY3009104 · Drug: Methotrexate
Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
Drug: LY3009104 · Drug: Methotrexate
Placebo administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
Drug: Placebo · Drug: Methotrexate
(Not utilized in Part A) After 12 weeks treatment with 1 mg LY3009104 once daily or Placebo once daily in Part A, administered orally twice daily for 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
Drug: LY3009104 · Drug: Methotrexate
Administered orally
Also known as: Janus Kinase (JAK)1/JAK2 Inhibitor, JAK1/2 Inhibitor, INCB028050, baricitinib
Administered orally
Administered orally as background therapy
Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.
Time frame: Baseline through Week 12
Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.
Time frame: Baseline through Week 12
Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 24
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) \* 100.
Time frame: Baseline through Weeks 2, 4, 8, 12, 16, 20, 24
Percentage of Participants Who Achieved an ACR20 Response Baseline Through Weeks 76 and 128
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.
Time frame: Baseline through Weeks 76 and 128
Percentage of Participants Who Achieved an ACR 50 Responder Index Response Baseline Through Week 24
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100.
Time frame: Baseline through Weeks 2, 4, 8, 12, 16, 20, 24
Percentage of Participants Who Achieved an ACR50 Response Baseline Through Weeks 76 and 128
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100.
Time frame: Baseline through Weeks 76 and 128
Percentage of Participants Who Achieved an ACR70 Responder Index Response Baseline Through Week 24
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100.
Time frame: Baseline through Weeks 2, 4, 8, 12, 16, 20, 24
Percentage of Participants Who Achieved an ACR70 Response Baseline Through Weeks 76 and 128
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100.
Time frame: Baseline through Weeks 76 and 128
Percentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.
Time frame: Baseline through Week 12
ACR Percent Improvement (ACR-N)
ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of a) % of improvement in TJC, b) % of improvement in SJC, and c) third highest percentage of improvement of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to a range of -100 to 100 to minimize impact of outliers (greater scores indicate greater % improvement) and negative scores indicate a decline. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.
Time frame: Baseline through Week 12
Mean Change From Baseline to Weeks 12 and 24 in Tender and Swollen Joint Counts (TJC and SJC)
TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.
Time frame: Baseline, Weeks 12 and 24
Mean Change From Baseline to Weeks 76 and 128 in TJC and SJC
TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.
Time frame: Baseline, Weeks 76 and 128
Mean Change From Baseline to Weeks 12 and 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
Time frame: Baseline, Weeks 12 and 24
Mean Change From Baseline to Weeks 76 and 128 in HAQ-DI Score
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
Time frame: Baseline, Weeks 76 and 128
Mean Change From Baseline to Weeks 12 and 24 in High-Sensitivity C-Reactive Protein (hsCRP)
hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.
Time frame: Baseline, Weeks 12 and 24
Mean Change From Baseline to Weeks 76 and 128 in hsCRP
hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.
Time frame: Baseline, Weeks 76 and 128
Mean Change From Baseline to Weeks 12 and 24 in Erythrocyte Sedimentation Rate (ESR)
ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.
Time frame: Baseline, Weeks 12 and 24
Mean Change From Baseline to Weeks 76 and 128 in ESR
ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.
Time frame: Baseline, Weeks 76 and 128
Mean Change From Baseline to Weeks 12 and 24 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain
Physician's and Patient's Assessments of Disease Activity (DA) assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeters (mm), where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis was also assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).
Time frame: Baseline, Weeks 12 and 24
Mean Change From Baseline to Weeks 76 and 128 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain
Physician's and Patient's assessments of DA assessed using a VAS that ranged from 0 to 100 mm, where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).
Time frame: Baseline, Weeks 76 and 128
Mean Change From Baseline to Weeks 12 and 24 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Baseline, Weeks 12 and 24
Mean Change From Baseline to Weeks 76 and 128 in DAS28-CRP
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Baseline, Weeks 76 and 128
Percentage of Responders According to European League Against Rheumatism Responder Index Based on 28-joint Count (EULAR28) Baseline Through Weeks 12 and 24
EULAR28 categorizes clinical response based upon improvement since baseline in DAS modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: TJC28, SJC28, CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \>0.6 units but ≤1.2 units or post-baseline DAS28 score \>3.2 with improvement by \>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \>1.2 units).
Time frame: Baseline through Weeks 12 and 24
Percentage of Responders According to EULAR28 Baseline Through Weeks 76 and 128
EULAR28 categorizes clinical response based upon improvement since baseline in Disease Activity Score modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \>0.6 units but ≤1.2 units or post-baseline DAS28 score \>3.2 with improvement by \>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \>1.2 units).
Time frame: Baseline, Weeks 76 and 128
Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 12 and 24
Disease Activity Score (DAS) modified to include 28-joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP \[milligrams per liter (mg/L)\], and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.
Time frame: Baseline through Weeks 12 and 24
Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 76 and 128
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.
Time frame: Baseline through Weeks 76 and 128
Mean Change From Baseline Through Week 12 in Duration (Minutes) of Morning Stiffness
The Investigator asked participants about the duration of their morning stiffness (in minutes) in and around the joints and recorded the duration. The Investigator asked the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.
Time frame: Baseline, Weeks 4, 8, 12
Mean Change From Baseline to Week 12 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains (physical functioning, bodily pain, role limitations due to physical problems and also emotional problems, general health, mental health, social functioning and vitality) and 2 component scores (PCS and MCS). The PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. The MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.
Time frame: Baseline, Week 12
Mean Change From Baseline to Week 12 in Brief Pain Inventory Modified Short Form (BPI-sf Modified) Worst-Pain-in-the Past-24-hours Item Score
The BPI-sf modified is a self-administered questionnaire developed for the rapid assessment of pain. The BPI-sf modified provides information on the intensity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The questionnaire asks questions about pain relief, pain quality, and the participant's perception of the cause of pain. The BPI-sf modified uses a numeric rating scale from 0 ("No pain") to 10 ("Pain as bad as you can imagine"). Since pain can be quite variable over a day, the BPI-sf modified asked participants to rate their pain at the time of responding to the questionnaire (right now), and also at its worst, least and average over the last 24 hours.
Time frame: Baseline, Week 12
Mean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score
The FACIT-F Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 ("Not at all") to 4 ("Very much") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.
Time frame: Baseline, Week 12
Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104
Time frame: Baseline through 24 weeks
Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104
Time frame: Baseline through 24 weeks
Mean Change From Baseline Through Week 12 in the ENSEMBLE Minimum Data Set 1.0
Time frame: Baseline, 12 weeks
| Milestone | 1 Milligrams (mg) LY3009104 QD - Part A | 2 mg LY3009104 QD - Parts A and B | 4 mg LY3009104 QD - Parts A and B | 8 mg LY3009104 QD - Parts A and B | Placebo QD - Part A | 2 mg LY3009104 BID - Part B | 4 mg LY3009104 QD - Part B | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 49 | 52 | 52 | 50 | 98 | 0 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 49 | 52 | 52 | 50 | 98 | 0 | 0 | 0 | 0 | 0 |
| Completed | 44 | 51 | 50 | 49 | 82 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 1 | 2 | 1 | 16 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 1 | 1 | 5 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Entry criteria not met | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Milestone | 1 Milligrams (mg) LY3009104 QD - Part A | 2 mg LY3009104 QD - Parts A and B | 4 mg LY3009104 QD - Parts A and B | 8 mg LY3009104 QD - Parts A and B | Placebo QD - Part A | 2 mg LY3009104 BID - Part B | 4 mg LY3009104 QD - Part B | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 51 | 50 | 49 | 0 | 63 | 63 | 0 | 0 | 0 |
| Completed | 0 | 50 | 48 | 45 | 0 | 59 | 57 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 2 | 4 | 0 | 4 | 6 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 2 | 0 | 3 | 4 | 0 | 0 | 0 |
| Withdrew: Entry criteria not met | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | 1 Milligrams (mg) LY3009104 QD - Part A | 2 mg LY3009104 QD - Parts A and B | 4 mg LY3009104 QD - Parts A and B | 8 mg LY3009104 QD - Parts A and B | Placebo QD - Part A | 2 mg LY3009104 BID - Part B | 4 mg LY3009104 QD - Part B | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 108 | 61 | 32 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 92 | 53 | 24 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 8 | 8 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Entry criteria not met | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Reason missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | 1 Milligrams (mg) LY3009104 QD - Part A | 2 mg LY3009104 QD - Parts A and B | 4 mg LY3009104 QD - Parts A and B | 8 mg LY3009104 QD - Parts A and B | Placebo QD - Part A | 2 mg LY3009104 BID - Part B | 4 mg LY3009104 QD - Part B | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 79 | 47 | 18 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 76 | 40 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 7 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.
| percentage of participants | 4 or 8 mg LY3009104 | Placebo |
|---|---|---|
| Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 | 76 | 41 |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.
| percentage of participants | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response | 54.6 (42.2 to 67.1) | 55.2 (42.3 to 67.6) | 74.3 (63.1 to 84.1) | 77.2 (65.9 to 86.7) | 42.1 (32.9 to 51.6) |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) \* 100.
| percentage of participants | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Week 2 | 29 | 21 | 42 | 44 | 11 |
| Week 4 | 43 | 37 | 60 | 54 | 24 |
| Week 8 | 43 | 42 | 67 | 72 | 36 |
| Week 12 | 57 | 54 | 75 | 78 | 41 |
| Week 16 | NA | 63 | 67 | 64 | NA |
| Week 20 | NA | 71 | 77 | 78 | NA |
| Week 24 | NA | 62 | 75 | 72 | NA |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.
| percentage of participants | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| Week 76 (n=108, 61, 32) | 71 | 67 | 59 |
| Week 128 (n=79, 47, 18) | 77 | 57 | 72 |
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100.
| percentage of participants | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Week 2 | 0 | 4 | 21 | 4 | 2 |
| Week 4 | 10 | 10 | 29 | 22 | 3 |
| Week 8 | 16 | 10 | 33 | 36 | 7 |
| Week 12 | 31 | 17 | 35 | 40 | 10 |
| Week 16 | NA | 19 | 38 | 44 | NA |
| Week 20 | NA | 27 | 46 | 48 | NA |
| Week 24 | NA | 19 | 46 | 54 | NA |
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100.
| percentage of participants | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| Week 76 (n=108, 61, 32) | 49 | 41 | 44 |
| Week 128 (n=79, 47, 18) | 58 | 30 | 44 |
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100.
| percentage of participants | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Week 2 | 0 | 2 | 12 | 0 | 0 |
| Week 4 | 2 | 4 | 10 | 6 | 0 |
| Week 8 | 4 | 4 | 15 | 22 | 0 |
| Week 12 | 12 | 8 | 23 | 20 | 2 |
| Week 16 | NA | 8 | 23 | 30 | NA |
| Week 20 | NA | 10 | 21 | 26 | NA |
| Week 24 | NA | 10 | 27 | 24 | NA |
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100.
| percentage of participants | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| Week 76 (n=108, 61, 32) | 29 | 18 | 25 |
| Week 128 (n=79, 47, 18) | 28 | 17 | 22 |
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.
| percentage of participants | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response | 26.5 (16.0 to 39.2) | 18.8 (9.9 to 29.7) | 34.4 (23.1 to 46.7) | 39.2 (27.1 to 52.2) | 12.0 (6.5 to 18.8) |
ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of a) % of improvement in TJC, b) % of improvement in SJC, and c) third highest percentage of improvement of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to a range of -100 to 100 to minimize impact of outliers (greater scores indicate greater % improvement) and negative scores indicate a decline. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.
| percentage of improvement | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| ACR Percent Improvement (ACR-N) | 17.30 (7.57 to 28.22) | 19.42 (8.74 to 29.25) | 28.59 (17.67 to 40.83) | 29.00 (17.67 to 41.47) | 10.97 (-0.39 to 21.64) |
TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.
| number of joints | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| TJC - Week 12 | -8.4 ± 12.70 | -11.3 ± 13.50 | -12.2 ± 10.45 | -14.7 ± 12.97 | -7.6 ± 12.31 |
| TJC - Week 24 | NA ± NA | -12.4 ± 12.60 | -14.0 ± 9.54 | -17.5 ± 11.23 | NA ± NA |
| SJC - Week 12 | -8.1 ± 7.24 | -8.9 ± 9.03 | -9.6 ± 6.49 | -10.4 ± 8.88 | -6.7 ± 7.97 |
| SJC - Week 24 | NA ± NA | -10.0 ± 8.16 | -10.5 ± 6.42 | -12.2 ± 7.29 | NA ± NA |
TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.
| units on a scale | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| TJC - Week 76 (n=108, 61, 32) | -15.7 ± 11.26 | -16.0 ± 13.37 | -18.1 ± 12.06 |
| TJC - Week 128 (n=79, 47, 18) | -16.4 ± 11.01 | -15.3 ± 12.56 | -14.0 ± 13.68 |
| SJC - Week 76 (n=108, 61, 32) | -11.6 ± 6.40 | -12.9 ± 7.80 | -12.4 ± 7.67 |
| SJC - Week 128 (n=79, 47, 18) | -11.4 ± 6.81 | -12.4 ± 8.01 | -11.6 ± 6.23 |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
| units on a scale | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Week 12 | -0.35 ± 0.528 | -0.18 ± 0.524 | -0.33 ± 0.459 | -0.39 ± 0.497 | -0.10 ± 0.406 |
| Week 24 | NA ± NA | -0.18 ± 0.505 | -0.32 ± 0.506 | -0.44 ± 0.529 | NA ± NA |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
| units on a scale | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| Week 76 (n=108, 61, 32) | -0.34 ± 0.58 | -0.29 ± 0.53 | -0.55 ± 0.58 |
| Week 128 (n=79, 47, 18) | -0.31 ± 0.61 | -0.22 ± 0.56 | -0.30 ± 0.66 |
hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.
| mg/L | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Week 12 | -6.14 ± 10.236 | -3.39 ± 19.409 | -7.06 ± 16.945 | -2.32 ± 32.582 | 1.50 ± 34.107 |
| Week 24 | NA ± NA | -4.76 ± 18.695 | -4.95 ± 19.819 | -7.61 ± 17.548 | NA ± NA |
hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.
| mg/L | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| Week 76 (n=108, 61, 32) | -3.9 ± 22.43 | -3.3 ± 14.28 | -2.9 ± 25.36 |
| Week 128 (n=79, 47, 18) | -6.8 ± 13.66 | -2.9 ± 21.88 | -8.2 ± 12.33 |
ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.
| mm/hr | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Week 12 (n=44, 51, 50, 49, 83) | -11.6 ± 14.45 | -6.4 ± 16.81 | -11.5 ± 17.28 | -13.9 ± 22.42 | -6.0 ± 19.49 |
| Week 24 (n=0, 50, 48, 45, 0) | NA ± NA | -6.9 ± 13.89 | -9.2 ± 19.00 | -13.7 ± 21.62 | NA ± NA |
ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.
| mm/hr | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| Week 76 (n=108, 61, 32) | -13.0 ± 18.84 | -7.4 ± 26.28 | -8.9 ± 23.12 |
| Week 128 (n=79, 47, 18) | -16.0 ± 18.74 | -8.5 ± 23.11 | -15.5 ± 23.07 |
Physician's and Patient's Assessments of Disease Activity (DA) assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeters (mm), where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis was also assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).
| units on a scale | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Physician's Assessment of DA - Week 12 | -23.9 ± 18.49 | -25.0 ± 20.81 | -30.4 ± 18.75 | -33.5 ± 19.49 | -19.0 ± 21.40 |
| Physician's Assessment of DA - Week 24 | NA ± NA | -27.8 ± 21.13 | -35.5 ± 17.72 | -37.8 ± 18.73 | NA ± NA |
| Patient's Assessment of DA - Week 12 | -24.9 ± 27.26 | -16.2 ± 22.43 | -25.4 ± 21.61 | -29.8 ± 21.20 | -10.3 ± 22.02 |
| Patient's Assessment of DA - Week 24 | NA ± NA | -16.9 ± 24.96 | -30.2 ± 21.85 | -30.0 ± 20.90 | NA ± NA |
| Patient's Assessment of Pain - Week 12 | -22.8 ± 27.39 | -14.2 ± 17.82 | -25.0 ± 19.22 | -25.3 ± 20.31 | -8.8 ± 22.77 |
| Patient's Assessment of Pain - Week 24 | NA ± NA | -14.7 ± 20.57 | -27.3 ± 22.11 | -26.9 ± 19.22 | NA ± NA |
Physician's and Patient's assessments of DA assessed using a VAS that ranged from 0 to 100 mm, where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).
| units on a scale | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| Physician Assessment of DA-Week 76 (n=108, 61, 32) | -40.3 ± 19.15 | -32.3 ± 23.37 | -40.5 ± 21.44 |
| Physician Assessment of DA-Week 128 (n=79, 47, 18) | -39.5 ± 20.32 | -31.0 ± 25.54 | -34.0 ± 27.51 |
| Patient Assessment of DA-Week 76 (n=108, 61, 32) | -27.5 ± 26.49 | -27.5 ± 25.52 | -27.6 ± 24.11 |
| Patient Assessment of DA-Week 128 (n=79, 47, 18) | -27.9 ± 27.40 | -19.3 ± 29.72 | -27.6 ± 25.17 |
| Patient Assessment of Pain-Week 76 (n=108, 61, 32) | -25.1 ± 24.10 | -27.3 ± 24.24 | -23.4 ± 23.49 |
| Patient Assessment of Pain-Week 128 (n=79, 47, 18) | -24.2 ± 24.35 | -18.0 ± 28.85 | -22.3 ± 22.99 |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| units on a scale | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Week 12 | -1.47 ± 1.299 | -1.40 ± 1.210 | -2.09 ± 1.220 | -2.15 ± 1.273 | -0.98 ± 1.141 |
| Week 24 | NA ± NA | -1.53 ± 1.187 | -2.25 ± 1.054 | -2.47 ± 1.280 | NA ± NA |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| units on a scale | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| Week 76 (n=107, 61, 31) | -2.47 ± 1.23 | -2.16 ± 1.28 | -2.68 ± 1.12 |
| Week 128 (n=79, 47, 18) | -2.56 ± 1.16 | -2.02 ± 1.23 | -2.35 ± 1.40 |
EULAR28 categorizes clinical response based upon improvement since baseline in DAS modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: TJC28, SJC28, CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \>0.6 units but ≤1.2 units or post-baseline DAS28 score \>3.2 with improvement by \>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \>1.2 units).
| percentage of participants | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Good Response - Week 12 | 22 | 17 | 46 | 40 | 16 |
| Moderate Response - Week 12 | 43 | 63 | 31 | 46 | 35 |
| No Response - Week 12 | 35 | 19 | 23 | 14 | 49 |
| Good Response - Week 24 | NA | 25 | 42 | 46 | NA |
| Moderate Response - Week 24 | NA | 52 | 42 | 32 | NA |
| No Response - Week 24 | NA | 23 | 15 | 22 | NA |
EULAR28 categorizes clinical response based upon improvement since baseline in Disease Activity Score modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \>0.6 units but ≤1.2 units or post-baseline DAS28 score \>3.2 with improvement by \>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \>1.2 units).
| percentage of participants | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| Good Response - Week 76 (n=107, 61, 31) | 64 | 41 | 55 |
| Moderate Response - Week 76 (n=107, 61, 31) | 27 | 46 | 39 |
| No Response - Week 76 (n=107, 61, 31) | 8 | 13 | 6 |
| Good Response - Week 128 (n=79, 47, 18) | 65 | 40 | 56 |
| Moderate Response - Week 128 (n=79, 47, 18) | 30 | 40 | 28 |
| No Response - Week 128 (n=79, 47, 18) | 5 | 19 | 17 |
Disease Activity Score (DAS) modified to include 28-joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP \[milligrams per liter (mg/L)\], and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.
| percentage of participants | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Low Disease Activity - Week 12 | 22 | 23 | 48 | 40 | 19 |
| Remission - Week 12 | 14 | 15 | 37 | 22 | 4 |
| Low Disease Activity - Week 24 | NA | 31 | 50 | 46 | NA |
| Remission - Week 24 | NA | 15 | 33 | 36 | NA |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.
| percentage of participants | 4 mg LY3009104 QD - Parts C and D | 4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D | 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D |
|---|---|---|---|
| Low Disease activity - Week 76 (n=108, 61, 32) | 58 | 38 | 44 |
| Remission - Week 76 (n=108, 61, 32) | 52 | 21 | 22 |
| Low Disease activity - Week 128 (n=79, 47, 18) | 59 | 36 | 56 |
| Remission - Week 128 (n=79, 47, 18) | 47 | 26 | 39 |
The Investigator asked participants about the duration of their morning stiffness (in minutes) in and around the joints and recorded the duration. The Investigator asked the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.
| minutes | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Week 4 (n=47, 50, 50, 50, 94) | -34.1 ± 70.49 | -27.0 ± 46.49 | -57.4 ± 149.00 | -25.5 ± 126.13 | -22.5 ± 63.61 |
| Week 8 (n=46, 50, 50, 50, 86) | -41.2 ± 85.45 | -31.1 ± 45.80 | -67.8 ± 138.02 | -53.8 ± 101.76 | -25.5 ± 67.39 |
| Week 12 (n=48, 51, 50, 50, 97) | -49.5 ± 72.80 | -30.7 ± 47.41 | -75.0 ± 142.04 | -62.7 ± 88.27 | -33.9 ± 91.79 |
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains (physical functioning, bodily pain, role limitations due to physical problems and also emotional problems, general health, mental health, social functioning and vitality) and 2 component scores (PCS and MCS). The PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. The MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.
| units on a scale | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| PCS | 6.66 ± 8.074 | 4.15 ± 7.680 | 7.07 ± 7.378 | 7.00 ± 9.054 | 3.22 ± 6.733 |
| MCS | 2.54 ± 11.983 | 1.89 ± 6.869 | 2.39 ± 7.898 | 3.03 ± 10.675 | 0.88 ± 10.437 |
The BPI-sf modified is a self-administered questionnaire developed for the rapid assessment of pain. The BPI-sf modified provides information on the intensity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The questionnaire asks questions about pain relief, pain quality, and the participant's perception of the cause of pain. The BPI-sf modified uses a numeric rating scale from 0 ("No pain") to 10 ("Pain as bad as you can imagine"). Since pain can be quite variable over a day, the BPI-sf modified asked participants to rate their pain at the time of responding to the questionnaire (right now), and also at its worst, least and average over the last 24 hours.
| units on a scale | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Mean Change From Baseline to Week 12 in Brief Pain Inventory Modified Short Form (BPI-sf Modified) Worst-Pain-in-the Past-24-hours Item Score | -1.35 ± 2.547 | -0.67 ± 2.132 | -1.41 ± 1.813 | -1.54 ± 2.131 | -0.35 ± 2.136 |
The FACIT-F Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 ("Not at all") to 4 ("Very much") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.
| units on a scale | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo |
|---|---|---|---|---|---|
| Mean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score | 4.48 ± 10.492 | 3.80 ± 9.152 | 4.41 ± 8.631 | 4.11 ± 9.971 | 2.02 ± 8.941 |
| nanomoles/Liter (nmol/L) | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 |
|---|---|---|---|---|
| Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104 | 36.5 ± 36.1 | 59.1 ± 21.3 | 119.0 ± 20.5 | 241.0 ± 22.9 |
| nanomoles*hour/Liter (nmol*h/L) | 1mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 |
|---|---|---|---|---|
| Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104 | 333 ± 61.7 | 541 ± 38.0 | 1060 ± 37.0 | 2190 ± 45.6 |
No measurements were reported for this outcome.
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 mg LY3009104 QD - Part A | — | 0/49 (0%) | 15/49 (30.6%) |
| 2 mg LY3009104 QD - Part A | — | 3/52 (5.8%) | 13/52 (25%) |
| 4 mg LY3009104 QD - Part A | — | 2/52 (3.8%) | 13/52 (25%) |
| 8 mg LY3009104 QD - Part A | — | 1/50 (2%) | 15/50 (30%) |
| Placebo QD - Part A | — | 3/98 (3.1%) | 18/98 (18.4%) |
| 2 mg LY3009104 BID Crossover- Part B | — | 2/63 (3.2%) | 15/63 (23.8%) |
| 4 mg LY3009104 QD Crossover- Part B | — | 1/63 (1.6%) | 10/63 (15.9%) |
| 2 mg LY3009104 QD - Part B | — | 0/51 (0%) | 12/51 (23.5%) |
| 4 mg LY3009104 QD - Part B | — | 0/50 (0%) | 10/50 (20%) |
| 8 mg LY3009104 QD - Part B | — | 3/49 (6.1%) | 18/49 (36.7%) |
| 4 mg LY3009104 QD - Part C | — | 16/108 (14.8%) | 35/108 (32.4%) |
| 4 to 8 mg LY3009104 QD Pre-Rescue - Part C | — | 1/61 (1.6%) | 7/61 (11.5%) |
| 4 to 8 mg LY3009104 QD Post-Rescue - Part C | — | 6/61 (9.8%) | 25/61 (41%) |
| 8 mg LY3009104 QD - Part C | — | 6/32 (18.8%) | 16/32 (50%) |
| 4 mg LY3009104 QD - Part D | — | 5/79 (6.3%) | 24/79 (30.4%) |
| 4 mg LY3009104 QD (4 to 8 mg Rescue)- Part D | — | 3/47 (6.4%) | 13/47 (27.7%) |
| 8/4 mg LY3009104 QD - Part D | — | 0/18 (0%) | 10/18 (55.6%) |
| Follow-Up | — | 2/159 (1.3%) | 5/159 (3.1%) |
| Event | 1 mg LY3009104 QD - Part A | 2 mg LY3009104 QD - Part A | 4 mg LY3009104 QD - Part A | 8 mg LY3009104 QD - Part A | Placebo QD - Part A | 2 mg LY3009104 BID Crossover- Part B | 4 mg LY3009104 QD Crossover- Part B | 2 mg LY3009104 QD - Part B | 4 mg LY3009104 QD - Part B | 8 mg LY3009104 QD - Part B | 4 mg LY3009104 QD - Part C | 4 to 8 mg LY3009104 QD Pre-Rescue - Part C | 4 to 8 mg LY3009104 QD Post-Rescue - Part C | 8 mg LY3009104 QD - Part C | 4 mg LY3009104 QD - Part D | 4 mg LY3009104 QD (4 to 8 mg Rescue)- Part D | 8/4 mg LY3009104 QD - Part D | Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/49 | 1/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 0/108 | 0/61 | 0/61 | 0/32 | 0/79 | 2/47 | 0/18 | 0/159 |
| Herpes zosterInfections and infestations | 0/49 | 0/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 4/108 | 0/61 | 0/61 | 1/32 | 1/79 | 0/47 | 0/18 | 0/159 |
| Myocardial infarctionCardiac disorders | 0/49 | 0/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 0/108 | 0/61 | 0/61 | 1/32 | 0/79 | 0/47 | 0/18 | 0/159 |
| Ulcerative keratitisEye disorders | 0/49 | 0/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 0/108 | 0/61 | 0/61 | 1/32 | 0/79 | 0/47 | 0/18 | 0/159 |
| ColitisGastrointestinal disorders | 0/49 | 0/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 0/108 | 0/61 | 1/61 | 1/32 | 0/79 | 0/47 | 0/18 | 0/159 |
| Acute hepatitis bInfections and infestations | 0/49 | 0/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 0/108 | 0/61 | 0/61 | 1/32 | 0/79 | 0/47 | 0/18 | 0/159 |
| DehydrationMetabolism and nutrition disorders | 0/49 | 0/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 1/108 | 0/61 | 0/61 | 1/32 | 0/79 | 1/47 | 0/18 | 0/159 |
| PresyncopeNervous system disorders | 0/49 | 0/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 0/108 | 0/61 | 0/61 | 1/32 | 0/79 | 0/47 | 0/18 | 0/159 |
| GastroenteritisInfections and infestations | 0/49 | 0/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 1/108 | 0/61 | 0/61 | 0/32 | 0/79 | 1/47 | 0/18 | 0/159 |
| SyncopeNervous system disorders | 0/49 | 0/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 0/108 | 0/61 | 0/61 | 0/32 | 0/79 | 1/47 | 0/18 | 0/159 |
| Event | 1 mg LY3009104 QD - Part A | 2 mg LY3009104 QD - Part A | 4 mg LY3009104 QD - Part A | 8 mg LY3009104 QD - Part A | Placebo QD - Part A | 2 mg LY3009104 BID Crossover- Part B | 4 mg LY3009104 QD Crossover- Part B | 2 mg LY3009104 QD - Part B | 4 mg LY3009104 QD - Part B | 8 mg LY3009104 QD - Part B | 4 mg LY3009104 QD - Part C | 4 to 8 mg LY3009104 QD Pre-Rescue - Part C | 4 to 8 mg LY3009104 QD Post-Rescue - Part C | 8 mg LY3009104 QD - Part C | 4 mg LY3009104 QD - Part D | 4 mg LY3009104 QD (4 to 8 mg Rescue)- Part D | 8/4 mg LY3009104 QD - Part D | Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BronchitisInfections and infestations | 1/49 | 1/52 | 2/52 | 1/50 | 3/98 | 1/63 | 2/63 | 2/51 | 0/50 | 0/49 | 9/108 | 0/61 | 3/61 | 5/32 | 3/79 | 2/47 | 1/18 | 1/159 |
| NasopharyngitisInfections and infestations | 0/49 | 0/52 | 2/52 | 1/50 | 2/98 | 1/63 | 0/63 | 0/51 | 0/50 | 2/49 | 2/108 | 0/61 | 4/61 | 1/32 | 7/79 | 2/47 | 2/18 | 0/159 |
| Urinary tract infectionInfections and infestations | 2/49 | 2/52 | 2/52 | 2/50 | 4/98 | 1/63 | 1/63 | 2/51 | 1/50 | 2/49 | 12/108 | 1/61 | 5/61 | 3/32 | 3/79 | 1/47 | 0/18 | 2/159 |
| Upper respiratory tract infectionInfections and infestations | 0/49 | 1/52 | 1/52 | 1/50 | 2/98 | 2/63 | 4/63 | 2/51 | 1/50 | 2/49 | 9/108 | 1/61 | 6/61 | 1/32 | 3/79 | 2/47 | 1/18 | 0/159 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 2/49 | 2/52 | 0/52 | 2/50 | 2/98 | 1/63 | 0/63 | 0/51 | 0/50 | 4/49 | 1/108 | 1/61 | 1/61 | 0/32 | 1/79 | 0/47 | 1/18 | 0/159 |
| HypertensionVascular disorders | 0/49 | 0/52 | 0/52 | 0/50 | 1/98 | 0/63 | 0/63 | 1/51 | 4/50 | 1/49 | 1/108 | 0/61 | 0/61 | 0/32 | 0/79 | 0/47 | 0/18 | 0/159 |
| Alanine aminotransferase increasedInvestigations | 0/49 | 1/52 | 0/52 | 1/50 | 3/98 | 0/63 | 0/63 | 1/51 | 1/50 | 1/49 | 1/108 | 0/61 | 0/61 | 0/32 | 1/79 | 3/47 | 0/18 | 0/159 |
| Low density lipoprotein increasedInvestigations | 0/49 | 0/52 | 1/52 | 1/50 | 2/98 | 4/63 | 1/63 | 1/51 | 1/50 | 3/49 | 0/108 | 0/61 | 0/61 | 0/32 | 3/79 | 0/47 | 0/18 | 0/159 |
| AnaemiaBlood and lymphatic system disorders | 0/49 | 0/52 | 2/52 | 0/50 | 0/98 | 1/63 | 0/63 | 0/51 | 0/50 | 1/49 | 0/108 | 1/61 | 0/61 | 2/32 | 1/79 | 1/47 | 0/18 | 0/159 |
| Irritable bowel syndromeGastrointestinal disorders | 0/49 | 0/52 | 0/52 | 0/50 | 0/98 | 0/63 | 0/63 | 0/51 | 0/50 | 0/49 | 0/108 | 0/61 | 0/61 | 2/32 | 0/79 | 0/47 | 0/18 | 0/159 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 53.1 ± 11.07 | 50.7 ± 13.12 | 52.5 ± 10.42 | 52.7 ± 10.91 | 49.2 ± 12.15 | 51.2 ± 11.71 |
| Sex: Female, Male(Participants) | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 42 | 44 | 37 | 41 | 85 | 249 |
| Male | 7 | 8 | 15 | 9 | 13 | 52 |
| Ethnicity (NIH/OMB)(Participants) | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 7 | 12 | 11 | 16 | 56 |
| Not Hispanic or Latino | 36 | 41 | 36 | 36 | 78 | 227 |
| Unknown or Not Reported | 3 | 4 | 4 | 3 | 4 | 18 |
| Race (NIH/OMB)(Participants) | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 3 | 3 | 2 | 7 | 19 |
| Asian | 8 | 8 | 7 | 9 | 15 | 47 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 2 | 2 | 6 | 11 |
| White | 37 | 40 | 40 | 37 | 70 | 224 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| United States | 16 | 16 | 16 | 16 | 31 | 95 |
| Hungary | 3 | 3 | 3 | 2 | 2 | 13 |
| Czech Republic | 4 | 3 | 6 | 3 | 7 | 23 |
| Mexico | 7 | 8 | 8 | 8 | 16 | 47 |
| Poland | 4 | 5 | 6 | 7 | 11 | 33 |
| Ukraine | 6 | 6 | 5 | 3 | 9 | 29 |
| Croatia | 0 | 1 | 0 | 1 | 5 | 7 |
| Romania | 2 | 2 | 1 | 3 | 3 | 11 |
| India | 7 | 8 | 7 | 7 | 14 | 43 |
| Duration of Rheumatoid Arthritis(years) | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 5.45 ± 3.885 | 5.53 ± 4.377 | 5.28 ± 4.466 | 6.63 ± 5.048 | 5.40 ± 4.283 | 5.62 ± 4.401 |
| Tender Joint Counts (TJC)(number of joints) | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 21.4 ± 10.90 | 23.0 ± 12.60 | 19.9 ± 12.71 | 24.4 ± 13.76 | 22.2 ± 12.06 | 22.2 ± 12.38 |
| Swollen Joint Counts (SJC)(number of joints) | 1 mg LY3009104 | 2 mg LY3009104 | 4 mg LY3009104 | 8 mg LY3009104 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 15.2 ± 6.55 | 17.0 ± 9.32 | 14.8 ± 7.54 | 16.1 ± 7.92 | 15.8 ± 8.64 | 15.8 ± 8.13 |
2 further baseline measures are reported on the registry.
The record gives a start of Oct 2010, a primary completion of Dec 2011 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 5 years 4 months after primary completion. A results delay was requested in Feb 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib